1. ����ҽ�ƴ�ѧ���������ٴ�ѧԺ�������е�������ҽԺ��
2. �����е�������ҽԺƤ����

��ժҪ�� ԭ����Ƥ��Tϸ���ܰ�����һ��ԭ����Ƥ�����ܰ�ϸ���쳣��ֳ�Լ�����ަ����ѿ����������������͡�ԭ����Ƥ��Tϸ���ܰ���������ѡ����Ҫȡ��������������֯-ŷ�ް�֢�о���������֯-����Ƥ���ܰ���ѧ���ƶ���TNMB����������׼��������Ҫ���ǵ����ذ��������Ʒ�������Ч�ʡ���Ч���������ʱ�䣬��������������ض������ã�����ʵʩ�����׳̶ȼ����Ʒ��õȡ�ԭ����Ƥ��Tϸ���ܰ�����������֧�����ƺ;ֲ�����Ϊ����������Ҫ�������ϻ��ƣ�����ݲ��鸨�����ߵ������ơ�һЩ�����ϸ�����ӡ�����¡������ں϶���Ҳ������������ԭ����Ƥ��Tϸ���ܰ�����

Hou Xiuli*��Wang Ping. *Affiliated Hangzhou Clinical College, Anhui Medical University, Hangzhou 310009, China Corresponding author: Wang Ping, Email: dermwang@aliyun.com ��Abstract�� Primary cutaneous T-cell lymphoma ��CTCL�� represents a group of diseases characterized by the abnormal proliferation of lymphocytes derived from the skin, with mycosis fungoides ��MF�� as the most common type. The choice of treatment for CTCL is mainly based on the tumor-node-metastasis-blood ��TNMB�� classification and staging system for cutaneous lymphomas proposed by the International Society for Cutaneous Lymphomas ��ISCL-World Health Organization-European Organization for Research and Treatment of Cancer ��EORTC�� in 2007. Other factors to be considered should include the time to onset of action and duration of sustained remission, as well as tolerability, side effects, convenience and cost of treatment. Supportive and local therapies are recommended for early CTCL, while systemic chemotherapy, with or without immunomodulatory therapy, is recommended for advanced CTCL. Some specific cytokines, monoclonal antibodies, and fusion toxins have been tried to treat CTCL.